Nevertheless, in our in vivo animal model, the combination of treatment with NK cells and anti‐PD‐L1 significantly reduced tumour growth, suggesting that the increase in tumour growth induced by BMP9 is only a temporary phenomenon occurring in the process of immunotherapy. This evidence concerns the gene GDF2 and neoplasm.